Ann: Successful Completion of Entitlement Offer, page-93

I'm with you on this. Efficacy for pain and function is the main game. I think we have Safety well covered, so Efficacy on Pain and Function is what gets us a label, and makes PAR a market darling. That's a winning lottery ticket in itself.

The EAP results on WOMAC were great, but this 008 study of 60 people on WOMAC is all i'm thinking about. Biomarker activity is of course important, and might be extremely important going forward - but I want an encouraging lookthrough to 002 results from the Pain and Function data on WOMAC which will come from 008. If it's anything like the EAP results, it'll be extremely exciting. Like you, i'm worried that due to the nature of 008 (which included drawing synovium samples directly from the knee joint, a painful process) will impact the reporting of data for the secondary endpoints.